1. Home
  2. PFS vs CGON Comparison

PFS vs CGON Comparison

Compare PFS & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PFS
  • CGON
  • Stock Information
  • Founded
  • PFS 1839
  • CGON 2010
  • Country
  • PFS United States
  • CGON United States
  • Employees
  • PFS N/A
  • CGON N/A
  • Industry
  • PFS Savings Institutions
  • CGON
  • Sector
  • PFS Finance
  • CGON
  • Exchange
  • PFS Nasdaq
  • CGON NYSE
  • Market Cap
  • PFS 2.5B
  • CGON 2.4B
  • IPO Year
  • PFS N/A
  • CGON 2024
  • Fundamental
  • Price
  • PFS $19.05
  • CGON $28.67
  • Analyst Decision
  • PFS Strong Buy
  • CGON Strong Buy
  • Analyst Count
  • PFS 5
  • CGON 8
  • Target Price
  • PFS $22.60
  • CGON $63.88
  • AVG Volume (30 Days)
  • PFS 622.8K
  • CGON 932.1K
  • Earning Date
  • PFS 01-23-2025
  • CGON 02-02-2025
  • Dividend Yield
  • PFS 5.04%
  • CGON N/A
  • EPS Growth
  • PFS N/A
  • CGON N/A
  • EPS
  • PFS 0.98
  • CGON N/A
  • Revenue
  • PFS $526,013,000.00
  • CGON $684,000.00
  • Revenue This Year
  • PFS N/A
  • CGON $162.50
  • Revenue Next Year
  • PFS $27.36
  • CGON $17.62
  • P/E Ratio
  • PFS $19.47
  • CGON N/A
  • Revenue Growth
  • PFS 13.26
  • CGON 258.12
  • 52 Week Low
  • PFS $13.07
  • CGON $25.77
  • 52 Week High
  • PFS $22.24
  • CGON $50.23
  • Technical
  • Relative Strength Index (RSI)
  • PFS 36.90
  • CGON 34.14
  • Support Level
  • PFS $20.07
  • CGON $27.00
  • Resistance Level
  • PFS $20.78
  • CGON $30.00
  • Average True Range (ATR)
  • PFS 0.59
  • CGON 2.03
  • MACD
  • PFS -0.27
  • CGON -0.42
  • Stochastic Oscillator
  • PFS 18.70
  • CGON 17.16

About PFS Provident Financial Services Inc

Provident Financial Services Inc is the holding company for The Provident Bank, a community-oriented bank. The Company's operations are solely in the financial services industry and include providing traditional banking and other financial services to its customers. The Company operates in the geographical regions of northern and central New Jersey, Queens and Nassau Counties in New York and eastern Pennsylvania. The Company has a single reporting segment for financial reporting purposes. The majority of the revenue-generating activities that are components of non-interest income are These revenue streams can generally be classified into three broad categories: wealth management revenue, insurance agency income, and banking service charges and other fees.

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Share on Social Networks: